| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514371000 | C=X bonded directly to the nitrogen which is bonded directly to the thiazole ring (X is chalcogen) | 41 |
| 20080207712 | THIAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS - The present invention relates to compounds of the Formula I | 08-28-2008 |
| 20080242709 | 2-AMIDO-4-ISOXAZOLYL THIAZOLE COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF - 2-Amido-4-isoxazolyl thiazole compounds exhibiting ATP-utilizing enzyme inhibitory activity, methods of using compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions comprising compounds exhibiting ATP-utilizing enzyme inhibitory activity, are disclosed. | 10-02-2008 |
| 20080293787 | PHARMACEUTICAL COMPOSITIONS FOR POORLY SOLUBLE DRUGS - The invention relates to solid dispersions of poorly soluble compounds formed by co-precipitation and hot melt extrusion, resulting in improved stability and bioavailability. The invention also relates to hot melt extrusion processes used to prepare such solid dispersions. | 11-27-2008 |
| 20080319033 | Organic Compounds - Compounds of formula I | 12-25-2008 |
| 20090048313 | 2-AMIDO-THIAZOLE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF - 2-Amido-4-substituted-aryl-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, methods of using compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions comprising compounds exhibiting ATP-utilizing enzyme inhibitory activity, are disclosed. | 02-19-2009 |
| 20090093530 | (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them - The present invention relates to novel (2R)-2-phenylpropanamides bearing a 4-sulfonylamino substituent on the 4 position of the phenyl group and to pharmaceutical compositions containing them, which are used as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells, and which are useful in the treatment of various ELR+CXC chemokine-mediated disorders. In particular, the compounds of the invention are useful in the treatment and control of specific CXCR2 dependent pathologies such as BOS, COPD, angiogenesis and melanoma. | 04-09-2009 |
| 20090143448 | NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES - Compounds of formula (I) | 06-04-2009 |
| 20090156652 | THERAPEUTIC AGENT FOR FOOD COMPETENCE DISORDER IN STOMACH - A therapeutic agent for impaired gastric accommodation which contains as an active ingredient a compound represented by the general formula (1): | 06-18-2009 |
| 20090192204 | N-(2-THIAZOLYL)-AMIDE DERIVATIVES AS GSK-3 INHIBITORS - The present invention relates to the use of N-(2-thiazolyl)-amide derivatives of formula (I) for the treatment and/or prophylaxis of a disease in which glycogen synthase kinase 3 (GSK-3) is involved, especially neurodegenerative diseases, such as Alzheimer's disease, or non-insulin dependent diabetes mellitus. | 07-30-2009 |
| 20090239919 | Glutamate receptor modulators and therapeutic agents - The present invention discloses methods of modulating the activity of Group I mGluRs using a defined class of benzamide compounds. In one embodiment, methods of modulating the activity of mGluR1 are provided. In another embodiment, methods of modulating the activity of mGluR5 are provided. In still another embodiment, methods of simultaneously modulating the activities of both mGluR1 and mGluR5 are provided. The present invention also provides methods of treating diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of benzamide compounds. The present invention further provides methods of preventing diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of compounds. Diseases and disorders contemplated include, inter alia, diseases and disorders of the central nervous system, the peripheral nervous system, the gastrointestinal system, the circulatory system, skin, retina, brain, heart, and lungs. | 09-24-2009 |
| 20090247593 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES - The invention relates to compounds of the formula I | 10-01-2009 |
| 20090258915 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE - Provided herein are novel compounds that inhibit ribonucleotide reductase (RR) by binding to RRM2 and interfering with the activity of the RRM1/RRM2 holoenzyme. These inhibitors may be used to inhibit RR activity and to treat various conditions associated with RRM2 expression, such as for example certain cancer types, mitochondrial diseases, or degenerative diseases. | 10-15-2009 |
| 20090281154 | Ophthalmic Compositions for Treating Ocular Hypertension - This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans. | 11-12-2009 |
| 20100093814 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF - The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, | 04-15-2010 |
| 20100105745 | Suppression of cancer and method for evaluating anticancer agent based on the effect of inhibiting gsk3 beta - It is intended to provide a novel means of treating and diagnosing cancer by clarifying the participation of glycogen synthase kinase 3β (GSK3β) in the survival and proliferation of cancer mils. Namely, a method of suppressing the survival and proliferation of cancer cells by inhibiting the expression of GSK3β or the activity of the above-described enzyme having been activated by the phosphorylation at the 216th tyrosine residue thereof; and a method of developing a novel anticancer agent and a method of evaluating an anticancer agent based on the inhibitory effect as described above. | 04-29-2010 |
| 20100137386 | TNIK INHIBITOR AND THE USE - The present invention relates to compositions and methods for the treatment of cancer patients with Traf2- and Nck-interacting kinase (TNIK) inhibitors. More particularly, the present invention relates to pharmaceutical compositions comprising TNIK inhibitor and a pharmaceutically acceptable carrier, and to methods for treating the TNIK inhibitor administered to cancer patients, especially to solid cancer patients such as colorectal cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer or breast cancer. | 06-03-2010 |
| 20100152256 | (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them - The present invention relates to novel (2R)-2-phenylpropanamides bearing a 4-sulfonylamino substituent on the 4 position of the phenyl group and to pharmaceutical compositions containing them, which are used as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells, and which are useful in the treatment of various ELR+CXC chemokine-mediated disorders. In particular, the compounds of the invention are useful in the treatment and control of specific CXCR2 dependent pathologies such as BOS, COPD, angiogenesis and melanoma. | 06-17-2010 |
| 20100210697 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CATARACT - The present invention aims to provide a pharmaceutical composition effective for the treatment of cataract. | 08-19-2010 |
| 20100267783 | PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY, AND INTERMEDIATE THEREFOR - An optically active 4-phenylthiazole derivative having a thrombopoietin receptor agonist activity and a pharmaceutical composition containing the present compound as an active ingredient are created, and a platelet production regulating agent which can be orally administered is provided. | 10-21-2010 |
| 20100273843 | HETEROCYCLIC SELF-IMMOLATIVE LINKERS AND CONJUGATES - The present invention provides heterocyclic linker compounds useful for linking drug moieties to ligands. The compounds also include drug-ligand conjugates comprising a ligand capable of targeting a selected cell population, and a drug connected to the ligand by a heterocyclic linker moiety. The linker moiety comprises a peptide sequence that is a substrate for an intracellular enzyme, for example a cathepsin, that cleaves the peptide at an amide bond. The peptide further contains a self-immolating moiety which connects the drug and the protein peptide sequence. Upon cleavage of the peptide sequence by an intracellular enzyme the self-immolating moiety cleaves itself from the drug moiety such that the drug moiety is in an underivatized and active form. | 10-28-2010 |
| 20100331379 | BENZAMIDE GLUCOKINASE ACTIVATORS - The present invention relates to N-heteroaryl-benzamides, pharmaceutical compositions comprising the same, and methods of using the same. The N-heteroaryl-benzamides are useful in diseases or medical conditions mediated by glucokinase. | 12-30-2010 |
| 20110015240 | THIAZOLE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR - The invention provides a thiazole derivative useful as a VAP-1 inhibitor, as well as a pharmaceutical agent for the prophylaxis or treatment of VAP-1 associated diseases and the like, a method of inhibiting VAP-1 in a subject, and a method for the prophylaxis or treatment of VAP-1 associated disease in a subject. The thiazole derivative is a compound represented by the formula (I): R | 01-20-2011 |
| 20110021582 | BENZOPHENONE THIAZOLE DERIVATIVES USEFUL FOR INHIBITING FORMATION OF MICROTUBULE AND METHOD FOR PRODUCING THE SAME - Disclosed are a novel thiazole-containing benzophenone derivative represented by formula 1, and an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof and a solvate thereof, a pharmaceutical composition comprising the derivative, a use of the derivative as therapeutic agent and a method for preparing the derivative. The benzophenone thiazole derivatives inhibit formation of microtubules and eliminate actively proliferating cells of malignant tumors to control general cell proliferation. In formula 1, R, R | 01-27-2011 |
| 20110028524 | PHARMACEUTICAL COMPOSITIONS FOR POORLY SOLUBLE DRUGS - The invention relates to solid dispersions of poorly soluble compounds formed by co-precipitation and hot melt extrusion, resulting in improved stability and bioavailability. The invention also relates to hot melt extrusion processes used to prepare such solid dispersions. | 02-03-2011 |
| 20110124693 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES - Compounds of Formula I: | 05-26-2011 |
| 20110245304 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE - Provided herein are novel compounds that inhibit ribonucleotide reductase (RR) by binding to RRM2 and interfering with the activity of the RRM1/RRM2 holoenzyme. These inhibitors may be used to inhibit RR activity and to treat various conditions associated with RRM2 expression, such as for example certain cancer types, mitochondrial diseases, or degenerative diseases. | 10-06-2011 |
| 20110245305 | PHARMACEUTICAL COMPOSITIONS FOR POORLY SOLUBLE DRUGS - The invention relates to solid dispersions of poorly soluble compounds formed by co-precipitation and hot melt extrusion, resulting in improved stability and bioavailability. The invention also relates to hot melt extrusion processes used to prepare such solid dispersions. | 10-06-2011 |
| 20110281922 | AMIDE THIAZOLE DERIVATIVE, PREPARATION METHOD AND USES THEREOF - The present invention relates to the field of drugs associated with treating diabetes. Particularly, the present invention relates to a dipeptidyl peptidase-IV inhibitor having the structure shown by formula (I), which contains amide thiazole structure and has an effect on treating diabetes, and a preparation method and a pharmaceutical composition containing it, as well as use thereof in manufacture of the drugs for treating the diabetes, | 11-17-2011 |
| 20120010257 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR - The present invention relates to modulators of cystic fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating CFTR mediated diseases using such modulators. | 01-12-2012 |
| 20120129898 | PHARMACEUTICAL COMPOSITIONS FOR POORLY SOLUBLE DRUGS - The invention relates to solid dispersions of poorly soluble compounds formed by co-precipitation and hot melt extrusion, resulting in improved stability and bioavailability. The invention also relates to hot melt extrusion processes used to prepare such solid dispersions. | 05-24-2012 |
| 20120270914 | SPLIT-LUCIFERASE C-MYC SENSOR AND USES THEREOF - A split luciferase-based sensor system was developed to noninvasively monitor and image phosphorylation-mediated c-Myc activation, in which the complementation of the split FL is induced by phosphorylation-mediated interaction between GSK3β and c-Myc. The complemented luciferase activity resulting from this interaction is specific to c-Myc phosphorylation and correlated with the steady-state and temporal regulation of c-Myc phosphorylation in cell culture. The sensor system also allows monitoring of c-Myc—targeted drug efficacy in intact cells and living animals. This new imaging sensor can provide insight into the role of functional c-Myc in cancer biology and is useful for the discovery and development of specific anti-c-Myc drugs. | 10-25-2012 |
| 20130059896 | 5-(1H-PYRAZOL-5-YL)THIAZOLE-BASED COMPOUNDS FOR THE TREATMENT OF DISEASES AND DISORDERS OF THE EYE - Inhibitors of LIM kinase 2 are disclosed, along with pharmaceutical compositions comprising them and methods of their use. Particular compounds are of the formula (I) | 03-07-2013 |
| 20130123313 | BENZOFURANONE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME - Provided is a novel compound having an effective anti-cancer activity. | 05-16-2013 |
| 20130150416 | Glutamate receptor modulators and therapeutic agents - The present invention discloses methods of modulating the activity of Group I mGluRs using a defined class of benzamide compounds. In one embodiment, methods of modulating the activity of mGluR1 are provided. In another embodiment, methods of modulating the activity of mGluR5 are provided. In still another embodiment, methods of simultaneously modulating the activities of both mGluR1 and mGluR5 are provided. The present invention also provides methods of treating diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of benzamide compounds. The present invention further provides methods of preventing diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of compounds. | 06-13-2013 |
| 20140121250 | ALKYLAMIDOTHIAZOLES, COSMETIC OR DERMATOLOGICAL PREPARATIONS CONTAINING SAID ALKYLAMIDOTHIAZOLES, AND USE THEREOF TO COMBAT OR PREVENT UNDESIRED PIGMENTATION OF THE SKIN - Alkylamidothiazoles of general formula (I), wherein R 1=—C1-C24 alkyl (linear and branched), —C1-C24 alkenyl (linear and branched), —C1-C8 cycloalkyl, —C1-C8 cycloalkyl-alkylhydroxy, —C1-C24 alkylhydroxy (linear and branched), —C1-C24 alkylamine (linear and branched), —C1-C24 alkylaryl (linear and branched), —C1-C24 alkylaryl-alkyl-hydroxy (linear and branched), —C1-C24 alkyl-heteroaryl (linear and branched), —C1-C24-alkyl-O—C1-C24-alkyl (linear and branched), —C1-C24 alkyl morpholino, —C1-C24 alkyl piperidino, —C1-C24 alkyl piperazino, —C1-C24 alkyl-piperazino-N-alkyl, as well as cosmetic or dermatological preparations having an effective content of one or more alkylamidothiazoles, as well as the use thereof for the cosmetic or dermatological treatment and/or prophylaxis of undesired skin pigmentation. | 05-01-2014 |
| 20140275189 | Methods for Modulating Bacterial Virulence and Related Compounds - The present invention relates to compounds and methods for the treatment of bacterial infections. The compounds and methods involve the disruption of the QseC signaling pathway which modulates the virulence of some bacteria. This methodology for treatment of bacterial infections reduces evolutionary pressure to develop resistance because the bacteria are not killed in the process. | 09-18-2014 |
| 20150126566 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator - The present invention relates to modulators of cystic fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating CFTR mediated diseases using such modulators. | 05-07-2015 |
| 20150141475 | THERAPEUTIC AGENT FOR FOOD COMPETENCE DISORDER IN STOMACH - A therapeutic agent for impaired gastric accommodation which contains as an active ingredient a compound represented by the general formula (1): | 05-21-2015 |
| 20150148385 | PHARMACEUTICAL COMPOSITION CONTAINING A COMPOUND HAVING A THROMBOPOIETIN RECEPTOR AGONISTIC ACTIVITY - The present inventor has found out that the following criteria enable to ensure an effect for increasing the platelet count while preventing an excessive increase in the platelet count; | 05-28-2015 |
| 20150368235 | Novel 2-Aminothiazole Derivative and Anti-Cancer Composition Comprising Same as Active Ingredient - The present invention relates to a novel 2-aminothiazole derivative, N-(5-(4-fluorophenyl)thiazole-2-il)-3-(furan-2-il)propane amide and to a use thereof as an anti-cancer drug. It is verified that the compound of the present invention has highly superior cancer cell-specific cytotoxic activity and in-vivo anti-cancer activity for inhibiting the growth of tumors in an animal model for cancer disease, and therefore can be developed as an anti-cancer candidate substance. | 12-24-2015 |
| 20160058738 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OVARY GRANULOSA CELL TUMORS CONTAINING GLYCOGEN SYNTHASE KINASE-3 BETA INHIBITOR AS ACTIVE INGREDIENT, AND FUNCTIONAL HEALTH FOOD COMPOSITION - A pharmaceutical composition for preventing or treating ovary granulosa cell tumors containing, as an active ingredient, one selected from the group consisting of a compound represented by chemical formula 1, a pharmaceutically acceptable salt of the compound represented by chemical formula 1, a compound represented by chemical formula 2, and a pharmaceutically acceptable salt of the compound represented by chemical formula 2, or a functional health food composition. The composition inhibits glycogen synthase kinase-3 beta (GSK3beta) and thus has an effect of inhibiting a phosphorylation of a serine, which is the 33rd amino acid of the forkhead box L2 (FOXL2) protein. | 03-03-2016 |
